I believe they earned 2 million on one mission suring the quarter and there was residual income from the previous quarter. Hence positive earnings? IMHO
As we approach the annual meeting, looking for small positive earnings for the recent quarter, and positive announcements about new Rigaku/1st Detect products.
Moving up on small volume! What does it mean. Small volume short sellers covering their postions? Wise to avoid news announcement when your short stock.
Huge portion of AGN stock is owned by employees. No Deal unless $200 per share paid and guaranteed fat severance packages.
There are very few sellers of Astrotech Corp stock. There was previously a large volume of buying between $2.60 and $2.70 and those are long term large investors who are not going to give up their shares. Every day in near future is going to bring news, annual meeting, quarterly earinings, Rigagu/1st Detect contracts, and possible Army detection device contracts.
"As we grow more reliant on networked automation, we must also ensure that these systems are better protected and far more resilient. SparkCognition's powerful technology and skilled team are well poised to deliver businesses the scale and security they require," said Tom B. Pickens III, Chairman of Astrotech Corporation (NASDAQ: ASTC).
May 3, 2014 S&P report shows 2700 shareholders. More Shareholders is a good thing. The trend appears to be upwards.
Nice to have a major launch near the Astrotech Corp. June 26, 2014 annual meeting.
A Tiny Stock That Could Disrupt the Entire Tech Market
by Stephen Petranek.
Posted May 1, 2014
I became interested in the company Astrotech (NASDAQ:ASTC) when I wrote on the new era of private space companies in February, featured in Tomorrow in Review.
I’m especially fond of the company’s division called 1st Detect, which has built a portable mass spectrometer.
The machines were developed during a contract with NASA, and now they’re being commercialized. I cannot overemphasize what a breakthrough this is.
When I was in college, the “mass spec” in the physics lab that I used was the size of an office, was incredibly complicated and sucked up massive amounts of power. Astrotech’s device weighs 12 pounds, is the size of a box of detergent and runs on a 12-volt battery.
Eureka! Here’s what a mass spec can do: tell you exactly what’s in anything, atom by atom.
A 1st Detect mass spec on the SOHO satellite studying the sun has told us that the solar wind isn’t just cosmic rays and streams of electrons, protons and neutrons — it’s neon, magnesium, carbon, silicon and iron.
see Yahoo Market Pulse April 116th, 2014 for information on SparkCognition or go to google finance latest news.
The April 28 State Department policy announcement reads in part:
“Effective immediately, the Department’s Directorate of Defense Trade Controls (DDTC) will deny pending applications for export or re-export of any high technology defense article or services regulated under the U.S. Munitions List to Russia or occupied Crimea that contribute to Russia’s military capabilities.
“In addition, the Department is taking action to revoke any existing export licenses which meet these conditions. All other pending applications and existing licenses will receive a case-by-case evaluation to determine their contribution to Russia’s military capabilities.”
U.S. Sanctions Putting the Brakes on Russia-bound Satellite Shipments
Canada Blocks Baikonur-bound Satellite Shipment over Ukraine Crisis
Now you are adding a zero to my posting name. It is amazing you persist in trying to disrupt this message board. The board authorities have been notified. Good luck with that.
Sentiment: Strong Buy
updates coming, whales demanding information, policy shift to provide multiple updates, good for stock share price
Allergan's legacy will not be remembered as selling out to an inferior overfinanced buyer. Johnson and Johnson or Merck are much better matches. Allergan can go to $200 on its new business coming. They don't even need a higher purchase offer. Valeant and Ackman will still be winners because they own so many shares. The gate is open for the share price to go straight up.
Sentiment: Strong Buy
■Narcotics & illicit street drugs
■Explosives & chemical warfare,
■In-line pharmaceutical processing,
■Authentication & anti-counterfeiting,
■Hazardous materials & chemical spills
■Incoming raw material ID.
Even a a dismal overall market, many buyers are taking stock around $2.70 per share. That means there is a nice upside from there. Any news should push the price to the $3.50 range.
If Johnson & Johnson or Merck show up to bid, they will take Allergan at $200/share. Allergan will not accept Valeant as a takeover candidate.
you continue to give asians a bad name
I am guessing, but Astrotech may earn one million on this OCO 2 NASA JET Propulsion Laboratory Mission.
Everybody knows ASTROTECH CORP is the best processor of Satellites. The Russians know it too. So bet on many of the Satellites that would have gone up on Russian Rockets to be processed by ASTC.
Shibani Malhotra, Sterne Agee: “We believe that Allergan will likely do all it can to resist a hostile takeover by Valeant. The company, however, has now been put “in play” and management would need to take transformative action in order to keep the company independent…We expect to see other potential suitors emerge for Allergan, especially from the large cap pharmaceuticals space. Allergan is a best-in-class company with an organic business that is rapidly growing and sustainable.”
Seamus Fernandez, Leerink Research: On whether a white night could appear for Allergan, Mr Fernandez writes: “Although several other companies would be potential fits for AGN, including GSK (MP), SNY, or NVS (OP), we believe only Nestle or perhaps NVS (with Alcon) could potentially compete with VRX on synergies and tax benefits. Nonetheless, each company (VRX, Nestle, and NVS) has potential antitrust overlap issues that warrant consideration.”